Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization

Dong Hyun Jo; Jin Hyoung Kim; Wonjun Yang; Hyori Kim; Shinjae Chang; Dongjo Kim; Minseok Chang; Kihwang Lee; Junho Chung; Jeong Hun Kim

doi:10.18632/oncotarget.17221

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization

Dong Hyun Jo, Jin Hyoung Kim, Wonjun Yang, Hyori Kim, Shinjae Chang, Dongjo Kim, Minseok Chang, Kihwang Lee, Junho Chung _ and Jeong Hun Kim

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:45506-45516. https://doi.org/10.18632/oncotarget.17221

Metrics: PDF 1921 views | HTML 3227 views | ?

Abstract

Dong Hyun Jo1,2, Jin Hyoung Kim1, Wonjun Yang3,4,5, Hyori Kim6, Shinjae Chang7, Dongjo Kim7, Minseok Chang7, Kihwang Lee8, Junho Chung3,4,5 and Jeong Hun Kim1,2,9

1Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea

2Department of Biomedical Sciences and Protein Metabolism, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea

3Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Republic of Korea

4Department of Cancer Biology, Seoul National University College of Medicine, Seoul, Republic of Korea

5Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

6Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea

7Biotechnology Research Institute, Celltrion, Inc., Incheon, Republic of Korea

8Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea

9Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence to:

Junho Chung, email: [email protected]

Jeong Hun Kim, email: [email protected]

Keywords: age-related macular degeneration, choroidal neovascularization, complement component 5, MG4 domain, therapeutic antibody

Received: January 31, 2017 Accepted: March 15, 2017 Published: April 19, 2017

ABSTRACT

Age-related macular degeneration (AMD) is one of the main causes of visual impairment in adults. Visual deterioration is more prominent in neovascular AMD with choroidal neovascularization (CNV). Clinical and postmortem studies suggested that complement system activation might induce CNV. In this study, we demonstrated that an anti-mouse complement component 5 (C5) antibody targeting MG4 domain of β chain effectively inhibited CNV which was induced by laser photocoagulation in mice. The targeted epitope of this anti-C5 antibody was different from that of currently utilized anti-C5 antibody (eculizumab) in the MG7 domain in which a single nucleotide polymorphism (R885H/C) results in poor response to eculizumab. Even with targeting MG4 domain, this anti-C5 antibody reduced production of C5a, monocyte chemoattractant protein-1 and vascular endothelial growth factor to prevent infiltration of F4/80-positive cells into CNV lesions and formation of CNV. Furthermore, anti-C5 antibody targeting MG4 domain induced no definite toxicity in normal retina. These results demonstrated that anti-C5 antibody targeting MG4 domain inhibited CNV in neovascular AMD.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17221

Publication Alerts

Research Papers:

Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization

Abstract